<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01220297</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-14913</org_study_id>
    <secondary_id>SU-09092009-3841</secondary_id>
    <secondary_id>BMT209</secondary_id>
    <nct_id>NCT01220297</nct_id>
  </id_info>
  <brief_title>Sirolimus &amp; Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT</brief_title>
  <official_title>Sirolimus and Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A continuation study of sirolimus and mycophenolate mofetil (MMF) for graft-vs-host disease
      (GvHD) prophylaxis for patients undergoing matched related allogeneic hematopoietic stem cell
      transplantation (HSCT) for acute and chronic leukemia, myelodysplastic syndrome (MDS), high
      risk non-Hodgkin lymphoma (NHL), or Hodgkin lymphoma (HL)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To explore the novel combination of sirolimus and mycophenolate mofetil (MMF) as
      graft-vs-host disease (GvHD) prevention in human leukocyte antigen (HLA)-matched related
      donor peripheral blood stem cell (PBSC) or marrow transplantation (BMT), collectively
      hematopoietic stem cell transplantation (HSCT). This study will report the toxicities
      associated with this drug combination.

      For all treatments and procedures, Study Day is based on the day of HSCT as Day 0.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual
  </why_stopped>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Graft-vs-Host Disease (GvHD) (Grade 2 to 4)</measure>
    <time_frame>100 days post-transplant</time_frame>
    <description>Assessed as the incidence of grade 2 to 4 acute graft-vs-host disease (GvHD) at Day 100 post-transplant.
Stage of Acute GvHD was assessed as follows.
Stage 1: Skin: rash &lt; 25% of skin. Liver: bilirubin 2 to 3 mg/dL. Gut: diarrhea &gt; 500 mL/day or persistent nausea with positive biopsy for GvHD
Stage 2: Skin: rash 25 to 50% of skin. Liver: bilirubin 3 to 6 mg/dL. Gut: diarrhea &gt;1000 mL/day.
Stage 3: Skin: rash &gt; 50% of skin. Liver: bilirubin 6 to 15 mg/dL. Gut: diarrhea &gt; 1500 mL/day.
Stage 4: Skin: generalized erythroderma with bulla formation. Liver: bilirubin &gt; 15 mg/dL. Gut: severe abdominal pain with or without ileus
Grade of Acute GvHD was determined as follows.
Grade 1: Stage 1-2 Skin + No Liver stage + No Gut stage
Grade 2: Stage 3 Skin OR Stage 1 Liver or Stage 1 Gut
Grade 3: No Skin stage + Stage 2 to 3 Liver Stage 2 to 4 Gut
Grade 4: Stage 4 Skin + or Stage 2 to 3 Liver + No Gut stage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute GvHD (Grade 3 to 4)</measure>
    <time_frame>100 days post-transplant</time_frame>
    <description>Assessed as the incidence of grade 3 to 4 acute GvHD at Day 100 post-transplant.
Stage of Acute GvHD was assessed as follows.
Stage 1: Skin: rash &lt; 25% of skin. Liver: bilirubin 2 to 3 mg/dL. Gut: diarrhea &gt; 500 mL/day or persistent nausea with positive biopsy for GvHD
Stage 2: Skin: rash 25 to 50% of skin. Liver: bilirubin 3 to 6 mg/dL. Gut: diarrhea &gt;1000 mL/day.
Stage 3: Skin: rash &gt; 50% of skin. Liver: bilirubin 6 to 15 mg/dL. Gut: diarrhea &gt; 1500 mL/day.
Stage 4: Skin: generalized erythroderma with bulla formation. Liver: bilirubin &gt; 15 mg/dL. Gut: severe abdominal pain with or without ileus
Grade of Acute GvHD was determined as follows.
Grade 1: Stage 1-2 Skin + No Liver stage + No Gut stage
Grade 2: Stage 3 Skin OR Stage 1 Liver or Stage 1 Gut
Grade 3: No Skin stage + Stage 2 to 3 Liver Stage 2 to 4 Gut
Grade 4: Stage 4 Skin + or Stage 2 to 3 Liver + No Gut stage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival (DFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Assessed as survival without recurrence of disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival is defined as time from enrollment to time of death or last follow-up, within 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Veno-occlusive Disease (VoD)</measure>
    <time_frame>100 days post-transplant</time_frame>
    <description>Assessed as the incidence of veno-occlusive disease (VoD) at 100 days post-transplant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Hematologic Diseases</condition>
  <condition>Acute-graft-versus-host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Non-Hodgkin Lymphoma (NHL)</condition>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Carmustine Etoposide Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carmustine + Etoposide + Cyclophosphamide followed by Sirolimus and Mycophenolate mofetil (MMF) as prophylaxis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FTBI + Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FTBI + Cyclophosphamide followed by Sirolimus and Mycophenolate mofetil (MMF) as prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Immunosuppressant administered orally to:
Adults (age 14 and older), beginning on Day -3 with 12 mg loading dose, followed by 4 mg/day.
Children &lt; 13 years or weighing 40 kg, beginning on Day -3 with 3 mg/m² loading dose, followed by 1 mg/ m², rounded to the nearest full milligram.
Daily dosage may be adjusted to maintain a target serum trough level of 3 to 12 ng/ml. Sirolimus dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months.</description>
    <arm_group_label>Carmustine Etoposide Cyclophosphamide</arm_group_label>
    <arm_group_label>FTBI + Cyclophosphamide</arm_group_label>
    <other_name>Rapamycin</other_name>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil (MMF)</intervention_name>
    <description>Immunosuppressant given intravenously (IV) at 15 mg/kg 3 times daily, starting on Day 0 ≥ 2 hr after the completion of the HSCT infusion. Dose of MMF will be based on actual body weight, but limited to 15 kg above ideal body weight. MMF dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months.</description>
    <arm_group_label>Carmustine Etoposide Cyclophosphamide</arm_group_label>
    <arm_group_label>FTBI + Cyclophosphamide</arm_group_label>
    <other_name>Cellcept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -6 at the lesser of 15 mg/kg or 550 mg/m².</description>
    <arm_group_label>Carmustine Etoposide Cyclophosphamide</arm_group_label>
    <other_name>Bis-chloroethylnitrosourea (BCNU, BiCNU)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -4 at 60 mg/kg</description>
    <arm_group_label>Carmustine Etoposide Cyclophosphamide</arm_group_label>
    <other_name>VP-16</other_name>
    <other_name>VP16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide (Cyclo, CY)</intervention_name>
    <description>Cyclophosphamide is a chemotherapy agent.
For FTBI + Cyclophosphamide cohort, administered IV on Day -3 and -2 at 60 mg/kg.
For Carmustine + Etoposide + Cyclophosphamide cohort, administered IV on Day -2 at 100 mg/kg</description>
    <arm_group_label>Carmustine Etoposide Cyclophosphamide</arm_group_label>
    <arm_group_label>FTBI + Cyclophosphamide</arm_group_label>
    <other_name>Cytophosphane</other_name>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTBI</intervention_name>
    <description>For FTBI + Cyclophosphamide cohort, administered as 1320 cGy delivered in 11 120 cGy fractions over 4 days starting on Day -7.</description>
    <arm_group_label>FTBI + Cyclophosphamide</arm_group_label>
    <other_name>total body irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  Acute myelogenous leukemia (AML), beyond 2nd remission or relapsed/refractory disease,
             age 2 to 60 years

          -  AML, in first or subsequent remission or relapsed/refractory disease, age 51 to 60
             years of age

          -  AML with multilineage dysplasia

          -  Acute lymphoblastic leukemia (ALL), beyond 2nd remission or relapsed/refractory
             disease, age 2 to 60 years

          -  ALL, age 51 - 60 years in first or subsequent remission or relapsed/refractory disease

          -  Chronic myeloid leukemia (CML), beyond 2nd chronic phase or in blast crisis

          -  Myelodysplastic syndrome (MDS), including World Health Organization
             (WHO)classifications of refractory anemia with excess blasts-1 (RAEB-1), RAEB-2 and
             therapy-related MDS

          -  MDS with poor long-term survival including myeloid metaplasia and myelofibrosis

          -  Myeloproliferative disorders

          -  High-risk non-Hodgkin lymphoma (NHL) in 1st emission

          -  Relapsed or refractory NHL

          -  Hodgkin lymphoma (HL) beyond first remission

          -  Males and females of any ethnic background, 2 to 60 years of age

          -  Karnofsky Performance Status (KPS) ≥ 70% or Lansky performance status &gt; 70% for
             patients &lt; 16 years of age.

          -  Related, matched-donor identified [6/6 human leukocyte antigen (HLA)-A, B and DRB1]

          -  Willingness to take oral medications during the transplantation period

          -  Ability to understand and the willingness to sign a written informed consent document

        EXCLUSION CRITERIA

          -  Prior myeloablative allogeneic or autologous hematopoietic stem cell transplant (HSCT)

          -  HIV infection

          -  Pregnant

          -  Lactating

          -  Evidence of uncontrolled active infection

          -  Serum creatinine &gt; 1.5 mg/dL or 24-hour creatinine clearance &lt; 50 mL/min

          -  Direct bilirubin, Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;
             2 x upper limit of normal (ULN)

          -  Carbon monoxide diffusing capacity (DlCO) &lt; 60% predicted (adults) OR and in-room air
             oxygen saturation &lt; 92% (children)

          -  Left ventricular ejection fraction &lt; 45% (adults) OR shortening fraction &lt;
             26%(children)

          -  Fasting cholesterol &gt; 300 mg/dL or Triglycerides &gt; 300 mg/dL while on lipid-lowering
             agents.

          -  Receiving investigational drugs unless cleared by the Principal Investigator (PI).

          -  Prior malignancies except basal cell carcinoma or treated carcinoma in-situ.

          -  Cancer treated with curative intent ≤ 5 years (EXCEPTION BY PI DISCRETION) (Cancer
             treated with curative intent &gt; 5 years will be allowed).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Johnston</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2009</study_first_submitted>
  <study_first_submitted_qc>October 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <results_first_submitted>March 13, 2017</results_first_submitted>
  <results_first_submitted_qc>May 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 5, 2017</results_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Laura Johnston</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Graft-vs-Host Disease (GvHD) Prophlyaxis</title>
          <description>Sirolimus &amp; Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GvHD Prophylaxis of Sirolimus &amp; MMF After BCNU+VP16+Cyclo</title>
          <description>Graft-vs-host disease (GvHD) prophylaxis of sirolimus &amp; mycophenolate mofetil (MMF) after chemotherapeutic regimen of carmustine (BCNU) + etoposide (VP-16) + cyclophosphamide (Cyclo)</description>
        </group>
        <group group_id="B2">
          <title>GvHD Prophylaxis of Sirolimus &amp; MMF After FTBI + Cyclo</title>
          <description>Graft-vs-host disease (GvHD) prophylaxis of sirolimus &amp; mycophenolate mofetil (MMF) after therapeutic regimen of cyclophosphamide (Cyclo) chemotherapy and fractionated total body irradiation (FTBI)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Characteristics</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Acute Lymphoblastic Leukemia (ALL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute Myeloid Leukemia (AML)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biphenotypic Acute Leukaemia (BAL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acute Graft-vs-Host Disease (GvHD) (Grade 2 to 4)</title>
        <description>Assessed as the incidence of grade 2 to 4 acute graft-vs-host disease (GvHD) at Day 100 post-transplant.
Stage of Acute GvHD was assessed as follows.
Stage 1: Skin: rash &lt; 25% of skin. Liver: bilirubin 2 to 3 mg/dL. Gut: diarrhea &gt; 500 mL/day or persistent nausea with positive biopsy for GvHD
Stage 2: Skin: rash 25 to 50% of skin. Liver: bilirubin 3 to 6 mg/dL. Gut: diarrhea &gt;1000 mL/day.
Stage 3: Skin: rash &gt; 50% of skin. Liver: bilirubin 6 to 15 mg/dL. Gut: diarrhea &gt; 1500 mL/day.
Stage 4: Skin: generalized erythroderma with bulla formation. Liver: bilirubin &gt; 15 mg/dL. Gut: severe abdominal pain with or without ileus
Grade of Acute GvHD was determined as follows.
Grade 1: Stage 1-2 Skin + No Liver stage + No Gut stage
Grade 2: Stage 3 Skin OR Stage 1 Liver or Stage 1 Gut
Grade 3: No Skin stage + Stage 2 to 3 Liver Stage 2 to 4 Gut
Grade 4: Stage 4 Skin + or Stage 2 to 3 Liver + No Gut stage</description>
        <time_frame>100 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GvHD Prophylaxis of Sirolimus &amp; MMF After BCNU+VP16+Cyclo</title>
            <description>Graft-vs-host disease (GvHD) prophylaxis of sirolimus &amp; mycophenolate mofetil (MMF) after chemotherapeutic regimen of carmustine (BCNU) + etoposide (VP-16) + cyclophosphamide (Cyclo)</description>
          </group>
          <group group_id="O2">
            <title>GvHD Prophylaxis of Sirolimus &amp; MMF After FTBI + Cyclo</title>
            <description>Graft-vs-host disease (GvHD) prophylaxis of sirolimus &amp; mycophenolate mofetil (MMF) after therapeutic regimen of cyclophosphamide (Cyclo) chemotherapy and fractionated total body irradiation (FTBI)</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Graft-vs-Host Disease (GvHD) (Grade 2 to 4)</title>
          <description>Assessed as the incidence of grade 2 to 4 acute graft-vs-host disease (GvHD) at Day 100 post-transplant.
Stage of Acute GvHD was assessed as follows.
Stage 1: Skin: rash &lt; 25% of skin. Liver: bilirubin 2 to 3 mg/dL. Gut: diarrhea &gt; 500 mL/day or persistent nausea with positive biopsy for GvHD
Stage 2: Skin: rash 25 to 50% of skin. Liver: bilirubin 3 to 6 mg/dL. Gut: diarrhea &gt;1000 mL/day.
Stage 3: Skin: rash &gt; 50% of skin. Liver: bilirubin 6 to 15 mg/dL. Gut: diarrhea &gt; 1500 mL/day.
Stage 4: Skin: generalized erythroderma with bulla formation. Liver: bilirubin &gt; 15 mg/dL. Gut: severe abdominal pain with or without ileus
Grade of Acute GvHD was determined as follows.
Grade 1: Stage 1-2 Skin + No Liver stage + No Gut stage
Grade 2: Stage 3 Skin OR Stage 1 Liver or Stage 1 Gut
Grade 3: No Skin stage + Stage 2 to 3 Liver Stage 2 to 4 Gut
Grade 4: Stage 4 Skin + or Stage 2 to 3 Liver + No Gut stage</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute GvHD (Grade 3 to 4)</title>
        <description>Assessed as the incidence of grade 3 to 4 acute GvHD at Day 100 post-transplant.
Stage of Acute GvHD was assessed as follows.
Stage 1: Skin: rash &lt; 25% of skin. Liver: bilirubin 2 to 3 mg/dL. Gut: diarrhea &gt; 500 mL/day or persistent nausea with positive biopsy for GvHD
Stage 2: Skin: rash 25 to 50% of skin. Liver: bilirubin 3 to 6 mg/dL. Gut: diarrhea &gt;1000 mL/day.
Stage 3: Skin: rash &gt; 50% of skin. Liver: bilirubin 6 to 15 mg/dL. Gut: diarrhea &gt; 1500 mL/day.
Stage 4: Skin: generalized erythroderma with bulla formation. Liver: bilirubin &gt; 15 mg/dL. Gut: severe abdominal pain with or without ileus
Grade of Acute GvHD was determined as follows.
Grade 1: Stage 1-2 Skin + No Liver stage + No Gut stage
Grade 2: Stage 3 Skin OR Stage 1 Liver or Stage 1 Gut
Grade 3: No Skin stage + Stage 2 to 3 Liver Stage 2 to 4 Gut
Grade 4: Stage 4 Skin + or Stage 2 to 3 Liver + No Gut stage</description>
        <time_frame>100 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GvHD Prophylaxis of Sirolimus &amp; MMF After BCNU+VP16+Cyclo</title>
            <description>Graft-vs-host disease (GvHD) prophylaxis of sirolimus &amp; mycophenolate mofetil (MMF) after chemotherapeutic regimen of carmustine (BCNU) + etoposide (VP-16) + cyclophosphamide (Cyclo)</description>
          </group>
          <group group_id="O2">
            <title>GvHD Prophylaxis of Sirolimus &amp; MMF After FTBI + Cyclo</title>
            <description>Graft-vs-host disease (GvHD) prophylaxis of sirolimus &amp; mycophenolate mofetil (MMF) after therapeutic regimen of cyclophosphamide (Cyclo) chemotherapy and fractionated total body irradiation (FTBI)</description>
          </group>
        </group_list>
        <measure>
          <title>Acute GvHD (Grade 3 to 4)</title>
          <description>Assessed as the incidence of grade 3 to 4 acute GvHD at Day 100 post-transplant.
Stage of Acute GvHD was assessed as follows.
Stage 1: Skin: rash &lt; 25% of skin. Liver: bilirubin 2 to 3 mg/dL. Gut: diarrhea &gt; 500 mL/day or persistent nausea with positive biopsy for GvHD
Stage 2: Skin: rash 25 to 50% of skin. Liver: bilirubin 3 to 6 mg/dL. Gut: diarrhea &gt;1000 mL/day.
Stage 3: Skin: rash &gt; 50% of skin. Liver: bilirubin 6 to 15 mg/dL. Gut: diarrhea &gt; 1500 mL/day.
Stage 4: Skin: generalized erythroderma with bulla formation. Liver: bilirubin &gt; 15 mg/dL. Gut: severe abdominal pain with or without ileus
Grade of Acute GvHD was determined as follows.
Grade 1: Stage 1-2 Skin + No Liver stage + No Gut stage
Grade 2: Stage 3 Skin OR Stage 1 Liver or Stage 1 Gut
Grade 3: No Skin stage + Stage 2 to 3 Liver Stage 2 to 4 Gut
Grade 4: Stage 4 Skin + or Stage 2 to 3 Liver + No Gut stage</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival (DFS)</title>
        <description>Assessed as survival without recurrence of disease</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GvHD Prophylaxis of Sirolimus &amp; MMF After BCNU+VP16+Cyclo</title>
            <description>Graft-vs-host disease (GvHD) prophylaxis of sirolimus &amp; mycophenolate mofetil (MMF) after chemotherapeutic regimen of carmustine (BCNU) + etoposide (VP-16) + cyclophosphamide (Cyclo)</description>
          </group>
          <group group_id="O2">
            <title>GvHD Prophylaxis of Sirolimus &amp; MMF After FTBI + Cyclo</title>
            <description>Graft-vs-host disease (GvHD) prophylaxis of sirolimus &amp; mycophenolate mofetil (MMF) after therapeutic regimen of cyclophosphamide (Cyclo) chemotherapy and fractionated total body irradiation (FTBI)</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival (DFS)</title>
          <description>Assessed as survival without recurrence of disease</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival is defined as time from enrollment to time of death or last follow-up, within 2 years.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GvHD Prophylaxis of Sirolimus &amp; MMF After BCNU+VP16+Cyclo</title>
            <description>Graft-vs-host disease (GvHD) prophylaxis of sirolimus &amp; mycophenolate mofetil (MMF) after chemotherapeutic regimen of carmustine (BCNU) + etoposide (VP-16) + cyclophosphamide (Cyclo)</description>
          </group>
          <group group_id="O2">
            <title>GvHD Prophylaxis of Sirolimus &amp; MMF After FTBI + Cyclo</title>
            <description>Graft-vs-host disease (GvHD) prophylaxis of sirolimus &amp; mycophenolate mofetil (MMF) after therapeutic regimen of cyclophosphamide (Cyclo) chemotherapy and fractionated total body irradiation (FTBI)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival is defined as time from enrollment to time of death or last follow-up, within 2 years.</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="405" lower_limit="72" upper_limit="423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Veno-occlusive Disease (VoD)</title>
        <description>Assessed as the incidence of veno-occlusive disease (VoD) at 100 days post-transplant.</description>
        <time_frame>100 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GvHD Prophylaxis of Sirolimus &amp; MMF After BCNU+VP16+Cyclo</title>
            <description>Graft-vs-host disease (GvHD) prophylaxis of sirolimus &amp; mycophenolate mofetil (MMF) after chemotherapeutic regimen of carmustine (BCNU) + etoposide (VP-16) + cyclophosphamide (Cyclo)</description>
          </group>
          <group group_id="O2">
            <title>GvHD Prophylaxis of Sirolimus &amp; MMF After FTBI + Cyclo</title>
            <description>Graft-vs-host disease (GvHD) prophylaxis of sirolimus &amp; mycophenolate mofetil (MMF) after therapeutic regimen of cyclophosphamide (Cyclo) chemotherapy and fractionated total body irradiation (FTBI)</description>
          </group>
        </group_list>
        <measure>
          <title>Veno-occlusive Disease (VoD)</title>
          <description>Assessed as the incidence of veno-occlusive disease (VoD) at 100 days post-transplant.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GvHD Prophylaxis of Sirolimus &amp; MMF After BCNU+VP16+Cyclo</title>
          <description>Graft-vs-host disease (GvHD) prophylaxis of sirolimus &amp; mycophenolate mofetil (MMF) after chemotherapeutic regimen of carmustine (BCNU) + etoposide (VP-16) + cyclophosphamide (Cyclo)</description>
        </group>
        <group group_id="E2">
          <title>GvHD Prophylaxis of Sirolimus &amp; MMF After FTBI + Cyclo</title>
          <description>Graft-vs-host disease (GvHD) prophylaxis of sirolimus &amp; mycophenolate mofetil (MMF) after therapeutic regimen of cyclophosphamide (Cyclo) chemotherapy and fractionated total body irradiation (FTBI)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>AML relapsed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vesicles</sub_title>
                <description>Bullae on right arm and torso</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Centrilobular nodularity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Acute graft vs host disease (GvHD)</sub_title>
                <description>Acute GvHD, with skin rash to trunk, upper back, pruritic at times</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>lung infection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Due to Pseudomonas bacteremia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Veno-occlusive disease (VOD)</sub_title>
                <description>Hepatobiliary/pancreas</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>including gross hematuria and/or clotted blood in urine</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Urgency to urinate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Lung (pneumonia)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>dry cough with intermittent sputum production</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Macular erythema</sub_title>
                <description>Macular erythema on chest/torso/shoulders (darkening confluent) with hyperpigmented macular rash on &gt; 50% body surface area (BSA).</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>(orthostatic hypotension)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal cramping</sub_title>
                <description>Including: Pain, swelling</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>BLE Numbness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>include: light headedness</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Madibular pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Klebsiella pneumoniae</sub_title>
                <description>Infection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Thrush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Multifocal Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand Pain</sub_title>
                <description>including: tremors</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Toe pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rigoring</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hemorrhoidal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Congestion, Nasal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <description>includes: limbs</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pressure ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Laura Johnston, MD</name_or_title>
      <organization>Stanford Univesity</organization>
      <phone>650-723-0822</phone>
      <email>laura.johnston@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

